Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27013497 | 0.97 | ALDH1A1 (0.39) | ALDH1A1LMNATP53NLRP3LOX | |
| SCHEMBL1908883 | 0.92 | ALDH1A1 (0.37) | ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL8812943 | 0.84 | — | — | |
| SCHEMBL8812357 | 0.82 | FAAH (0.31) | — | |
| SCHEMBL8813813 | 0.82 | FAAH (0.31) | — | |
| SCHEMBL2625547 | 0.80 | NLRP3 (0.38) | ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL777321 | 0.80 | ALDH1A1 (0.52) | ALDH1A1LMNATP53NLRP3LOX | |
| SCHEMBL6736117 | 0.77 | APP (0.44) | LMNA | |
| SCHEMBL13668109 | 0.77 | CA2 (0.37) | — | |
| SCHEMBL26504504 | 0.77 | CA2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-09-28 | — | — | US | disclosed |
| US-9629924-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2017-04-25 | — | — | US | disclosed |
| US-20160304548-A1 | Derivatives of Amphotericin B | ELION THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | BYONDIS B.V. (NL) | 2013-08-29 | — | — | US | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | NKUADA, LLC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | NKUADA, LLC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080319044-A1 | Compounds and Methods of Use Thereof | NUADA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080269204-A1 | Compounds and Methods of Use Thereof | DYAKONOV TATYANA | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | ALDH1A1 2514/4885LMNA 2614/4885TP53 214/4885 |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | TNF, IL1B, TNFRSF1A | ALDH1A1 830/4885LMNA 1421/4885TP53 441/4885 |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | ALDH1A1 2514/4885LMNA 2614/4885TP53 214/4885 |
| US-20160304548-A1 | Derivatives of Amphotericin B | C9, ERG28, AMPD3 | ALDH1A1 2372/4885LMNA 2238/4885TP53 4471/4885 |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | CYP3A5, QDPR, DPYD | ALDH1A1 178/4885LMNA 4387/4885TP53 4317/4885 |
| US-20080269204-A1 | Compounds and Methods of Use Thereof | TNF, LITAF, TNFRSF1A | ALDH1A1 946/4885LMNA 574/4885TP53 521/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | ALDH1A1 2514/4885LMNA 2614/4885TP53 214/4885 |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | TNF, NFKBIA, IL6 | ALDH1A1 531/4885LMNA 1527/4885TP53 327/4885 |
| US-20080319044-A1 | Compounds and Methods of Use Thereof | TNF, LITAF, LTA | ALDH1A1 1349/4885LMNA 1853/4885TP53 200/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | ALDH1A1 2514/4885LMNA 2614/4885TP53 214/4885 |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | PCNA, DCLRE1A, CDC5L | ALDH1A1 2514/4885LMNA 2614/4885TP53 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.